EMA Authorised: Libtayo (cemiplimab) — Regeneron Ireland Designated Activity Company (DAC)

View source ↗

Summary

The European Medicines Agency authorised Libtayo (cemiplimab) for the treatment of cutaneous squamous cell carcinoma (CSCC). Regeneron Ireland Designated Activi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Squamous Cell. MAH: Regeneron Ireland Designated Activity Company (DAC). Decision date: 17/11/2025